Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8461333 | VIIV HLTHCARE | Salts of prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(1 year, 8 months from now) | |
US7745625 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Nov, 2027
(4 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8168615 | VIIV HLTHCARE | Prodrugs of piperazine and substituted piperidine antiviral agents |
Feb, 2025
(1 year, 8 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Chemical Entity Exclusivity (NCE) | Jul 2, 2025 |
NCE-1 date: 2024-07-02
Market Authorisation Date: 02 July, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE;ORAL
16
United States
2
Hong Kong
2
China
2
New Zealand
2
Israel
1
Poland
1
Canada
1
Georgia
1
Slovenia
1
Korea, Republic of
1
Ukraine
1
Brazil
1
Taiwan
1
Germany
1
RS
1
Japan
1
Cyprus
1
Denmark
1
Croatia
1
Malaysia
1
Argentina
1
Spain
1
Australia
1
Norway
1
South Africa
1
Austria
1
Portugal
1
Russia
1
Peru
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic